Ventyx Biosciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Ventyx Biosciences filed supplemental disclosures regarding its proposed $14.00 per share cash merger with Eli Lilly, including financial analysis updates, partnership projections, and details on shareholder lawsuits.
Ventyx Biosciences' Board approved cash bonus awards for executives, replacing 2026 equity grants, contingent on the anticipated merger with Eli Lilly and Company.
Ventyx Biosciences has agreed to be acquired by Eli Lilly, a transaction expected to close in the first half of 2026.
Eli Lilly and Company will acquire Ventyx Biosciences, Inc. for $1.2 billion in an all-cash transaction, offering shareholders a 62% premium.
Ventyx Biosciences announced an agreement to be acquired by Eli Lilly, expecting to close the transaction in the first half of 2026.
Ventyx Biosciences announced an agreement to be acquired by Eli Lilly for $14.00 per share in cash, representing a 62% premium.
Ventyx Biosciences announces an agreement to be acquired by Eli Lilly, with the transaction expected to close in the first half of 2026.
Ventyx Biosciences announces its acquisition by Eli Lilly and Company for $14.00 per share in cash, expected to close in the first half of 2026.
Ventyx Biosciences has entered into a definitive agreement to be acquired by Eli Lilly and Company, aiming to enhance patient impact in autoimmune, inflammatory, and neurodegenerative diseases.
Ventyx Biosciences announced its agreement to be acquired by Eli Lilly for $14.00 per share in cash, a move expected to advance its pipeline in autoimmune, inflammatory, and neurodegenerative diseases.
Eli Lilly and Company announced a definitive agreement to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company, for approximately $1.2 billion in cash.
Ventyx Biosciences will hold its annual stockholders meeting on June 4, 2025, to elect directors, approve executive compensation, and ratify the appointment of Ernst & Young LLP as the independent auditor.
Ventyx Biosciences announces its 2025 annual meeting of stockholders to be held virtually on June 4, 2025, featuring proposals for director elections, executive compensation advisory vote, and ratification of the independent accounting firm.
Ventyx Biosciences will hold its annual stockholders meeting on June 5, 2024, to vote on the election of directors, executive compensation, the frequency of say-on-pay votes, and the ratification of the company's independent auditor.
Ventyx Biosciences will hold its 2024 annual meeting of stockholders virtually on June 5, 2024, to vote on the election of directors, executive compensation, the frequency of say-on-pay votes, and the ratification of the company's independent auditor.